tirzepatide phase 3 study results Efficacy and safety of in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, trial Tirzepatide for the Treatment of

In 2026, manufacturer cash-pay programs from Novo Nordisk and Eli Lilly have slashed self-pay costs to $199$449 per month depending on the drug and dose

However, some patients report leg discomfort potentially related to rapid weight loss, electrolyte imbalances from gastrointestinal side effects, or increased physical activity rather than direct drug effects

By increasing the time it takes for food to leave the body, it also slows digestion

s-glutathionylation) or factors, such as active site availability, substrate availability, and kinetic of the reaction might play a role in the stability of these complexes